UnitedHealth shares slump — is the US healthcare industry in trouble?
The murder of UnitedHealthcare’s CEO has shone a spotlight on a struggling US healthcare industry with an inauspicious outlook
Shares in UnitedHealth slumped by 10% following the fatal shooting of UnitedHealthcare’s CEO Brian Thompson on 4 December. Many people were “indifferent” to the assassination, with the group’s business practices in the spotlight instead. Some lambasted the group for “placing greater emphasis on their bottom line [than] providing quality coverage to its insurees”. Some investors worry that UnitedHealth “will see reduced customer loyalty, resulting in worse financial performance”.
It’s not only UnitedHealth, which saw its market capitalisation fall by $55 billion, that is facing pressure, says Forbes’ Derek Saul. There has been a wider sell-off in health insurance shares with a range of companies, such as Elevance Health, Cigna, Centene and Humana all losing ground. The fear seems to be that the anti-insurer sentiment expressed by the public may pressure the industry “to adjust how they handle coverage decisions”. If companies don’t, they know that they might eventually “face the wrath of the public” in the form of increased regulation.
Thompson appears to have become “a proxy for the healthcare industry writ large”, says Bloomberg’s Lisa Jarvis. The big question is whether this rage is channelled into something useful, at a time when the incoming Trump administration “seems keen to find cuts in ways that will directly harm Americans’ access to care, whether by making insurance less affordable or through deep cuts to Medicaid”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
For now, most analysts still expect the new administration to focus on “traditional Republican priorities”, such as trying to shift more patients into the privately administered programme known as Medicare Advantage, says David Wainer in The Wall Street Journal.
However, even under Trump, Republicans could be willing to pursue greater scrutiny on certain practices by insurers such as the requirement for a doctor to secure approval before providing a service, which the Biden administration had already “begun cracking down on”. At the very least, insurance executives could be forced to “tread more carefully when it comes to denying medical claims” in future.
Overall, something is very wrong with the US healthcare system, says Robert Cyran for Breakingviews – “only 5% of respondents ranked the services provided by health insurers as excellent in a 2023 Gallup poll, with about a third classifying them as poor”.
What’s more, despite the US spending $12,000 per head on healthcare, 2.5 times the average for countries in the Organisation for Economic Cooperation and Development, Americans still have “a lower life expectancy than most countries in the bloc”. Insurance premiums and out-of-pocket spending by individuals have also risen above inflation, with the US “spending more money and time on insurance, administration, patient paperwork, cost disputes and bickering over insurer approval for treatments”.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

-
‘Why I have ditched my Help to Buy ISA for cash savings and the stock market’Without the 25% bonus, my Help to Buy ISA is effectively redundant, says MoneyWeek writer Sam Walker.
-
Is your inheritance tax allowance cut if you sell to downsize or sell your home to pay for care?Downsizing relief is a little-known benefit that could save your loved ones tens of thousands of pounds in inheritance tax after you’ve died.
-
Stock markets have a mountain to climb: opt for resilience, growth and valueOpinion Julian Wheeler, partner and US equity specialist, Shard Capital, highlights three US stocks where he would put his money
-
The steady rise of stablecoinsInnovations in cryptocurrency have created stablecoins, a new form of money. Trump is an enthusiastic supporter, but its benefits are not yet clear
-
SRT Marine Systems: A leader in marine technologySRT Marine Systems is thriving and has a bulging order book, says Dr Michael Tubbs
-
Goodwin: A superlative British manufacturer to buy nowVeteran engineering group Goodwin has created a new profit engine. But following its tremendous run, can investors still afford the shares?
-
A change in leadership: Is US stock market exceptionalism over?US stocks trailed the rest of the world in 2025. Is this a sign that a long-overdue shift is underway?
-
A reckoning is coming for unnecessary investment trustsInvestment trusts that don’t use their structural advantages will find it increasingly hard to survive, says Rupert Hargreaves
-
Modern Monetary Theory and the return of magical thinkingThe Modern Monetary Theory is back in fashion again. How worried should we be?
-
Metals and AI power emerging marketsThis year’s big emerging market winners have tended to offer exposure to one of 2025’s two winning trends – AI-focused tech and the global metals rally